Omeros (NASDAQ:OMER) Stock Price Up 8.2% – Still a Buy?

Omeros Corporation (NASDAQ:OMER) shares rose 8.2% on Wednesday . The company traded as high as $10.28 and last traded at $10.2050. Approximately 843,103 shares changed hands during trading, a decline of 48% from the average daily volume of 1,626,645 shares. The stock had previously closed at $9.43.

Wall Street Analyst Weigh In

Several analysts recently commented on OMER shares. Wall Street Zen lowered Omeros from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Wednesday, October 15th. D. Boral Capital reissued a “buy” rating and set a $36.00 price objective on shares of Omeros in a research note on Monday. WBB Securities reiterated a “strong-buy” rating and set a $45.00 price objective on shares of Omeros in a report on Wednesday, October 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Omeros has a consensus rating of “Moderate Buy” and a consensus target price of $33.67.

Omeros Price Performance

The stock has a 50 day moving average price of $6.98 and a two-hundred day moving average price of $4.87. The firm has a market capitalization of $739.06 million, a price-to-earnings ratio of -5.15 and a beta of 2.48.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.39. As a group, research analysts expect that Omeros Corporation will post -3.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Omeros

Several institutional investors have recently modified their holdings of OMER. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Omeros in the second quarter valued at about $32,000. Harbour Investments Inc. grew its position in Omeros by 46.1% in the second quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 4,251 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Omeros by 829.6% during the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 11,971 shares in the last quarter. Sei Investments Co. acquired a new stake in Omeros during the 2nd quarter valued at $40,000. Finally, Russell Investments Group Ltd. grew its position in shares of Omeros by 113.1% during the third quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 5,677 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.